Product Name:
Lornoxicam CAS No.:
70374-39-9
Product Data Sheet
Cat. No.:
HY-B0367MWt:
371.82Formula:
C13H10ClN3O4S2Purity :
>98%
Solubility:Mechanisms:
Biological Activity:
Pathways:Immunology/Inflammation; Target:COX DMSO 2 mg/mL; Water <1 mg/mL
g y Lornoxicam, a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID).
Target: COX Lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005
microM/0.008 microM) of the large panel of NSAIDs tested. lornoxicam showed a marked inhibition of IL-6 formation (IC50 54 microM) while the formation ofTNF-alpha, IL-1beta and IL-8 was only moderately affected [1]. Lornoxicam is effective in the treatment of patients with activated
osteoarthritis; the analgesic and anti-inflammatory effects of lornoxicam are significantly superior to those of rofecoxib without inferiority in tolerability [2]. Lornoxicam was fully effective for prevention of References:
[1]. Berg, J., et al., The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res, 1999.
48(7): p. 369-79.[2]. Rose, P. and C. Steinhauser, Comparison of Lornoxicam and Rofecoxib in Patients with y y []y p
hyperalgesia [3]....
[]p
Activated Osteoarthritis (COLOR Study). Clin Drug Investig, 2004. 24(4): p. 227-36.[3]. Bianchi, M. and A.E. Panerai, Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res, 2002. 45(2):
p. 101-5.Caution: Not fully tested. For research purposes only
Medchemexpress LLC
https://www.wendangku.net/doc/618755931.html,
18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m